TY - JOUR
T1 - Diagnostic value of carbohydrate antigens in supernatants and sediments of pleural effusions
AU - Terracciano, Daniela
AU - Mazzarella, Claudia
AU - Cicalese, Marcellino
AU - Galzerano, Sonia
AU - Apostolico, Gianfranco
AU - Di Carlo, Angelina
AU - Mariano, Angela
AU - Cecere, Ciriaco
AU - Macchia, Vincenzo
PY - 2010/5
Y1 - 2010/5
N2 - A panel of tumour markers including carcinoembryonic antigen (CEA), carbohydrate antigen (Ca)15-3, Ca125 and Ca19-9 were measured in the lysate of sediments and in the supernatants of pleural effusions of patients with benign and malignant disease. The tumour markers were also measured in the serum of the same patients. Of these patients, 32 had benign diseases (12 trasudative effusions associated with cirrhosis and 20 with non-malignant exudates: 12 pleuritis and 8 other inflammations) and 103 had malignant effusions (37 breast cancers, 29 lung cancers, 10 ovary cancers, 6 kidney cancers, 11 mesotheliomas and 10 lymphomas). We showed the highest level of CEA in pleural effusions of lung cancer followed by that in pleural effusions of breast cancer; whereas Ca15-3 was very high in the pleural effusions of breast and lung cancer. Concerning the lysate of sediment, CEA was high in the pleural effusions of patients with lung cancer and Ca15-3 in those of patients with breast cancer. The other markers are much less useful. For the remaining tumours, none of the markers tested appear to aid in the diagnosis of disease. In conclusion, our data suggest that the combined determination of tumour markers on supernatants and sediments of pleural effusion may provide additional information on the nature of pleural effusion, especially for cases with negative cytology.
AB - A panel of tumour markers including carcinoembryonic antigen (CEA), carbohydrate antigen (Ca)15-3, Ca125 and Ca19-9 were measured in the lysate of sediments and in the supernatants of pleural effusions of patients with benign and malignant disease. The tumour markers were also measured in the serum of the same patients. Of these patients, 32 had benign diseases (12 trasudative effusions associated with cirrhosis and 20 with non-malignant exudates: 12 pleuritis and 8 other inflammations) and 103 had malignant effusions (37 breast cancers, 29 lung cancers, 10 ovary cancers, 6 kidney cancers, 11 mesotheliomas and 10 lymphomas). We showed the highest level of CEA in pleural effusions of lung cancer followed by that in pleural effusions of breast cancer; whereas Ca15-3 was very high in the pleural effusions of breast and lung cancer. Concerning the lysate of sediment, CEA was high in the pleural effusions of patients with lung cancer and Ca15-3 in those of patients with breast cancer. The other markers are much less useful. For the remaining tumours, none of the markers tested appear to aid in the diagnosis of disease. In conclusion, our data suggest that the combined determination of tumour markers on supernatants and sediments of pleural effusion may provide additional information on the nature of pleural effusion, especially for cases with negative cytology.
KW - Carbohydrate antigen 125
KW - Carbohydrate antigen 15-3
KW - Carcinoembryonic antigen
KW - Pleural effusions
UR - http://www.scopus.com/inward/record.url?scp=77955752075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955752075&partnerID=8YFLogxK
U2 - 10.3892/ol_00000082
DO - 10.3892/ol_00000082
M3 - Article
AN - SCOPUS:77955752075
SN - 1792-1074
VL - 1
SP - 465
EP - 471
JO - Oncology Letters
JF - Oncology Letters
IS - 3
ER -